These health startups raised $124M in venture capital funding this week
Although the Covid-19 pandemic has continued its relentless spread across the globe, several startup companies have closed venture capital funding rounds this week.
Although the Covid-19 pandemic has continued its relentless spread across the globe, several startup companies have closed venture capital funding rounds this week.
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Many proteins known to play roles in cancers are considered "undruggable" because they lack pockets for drugs to bind to. Amgen drew attention at ASCO with data on a drug targeting a KRAS mutation, generally considered not amenable to pharmaceutical therapy.
The firm will follow a model similar to that of BridgeBio, partnering with scientific researchers and launching companies to develop and commercialize their products.
The company plans to invest the money across several therapeutic areas and modalities, including oncology, immunology, gene and cell therapies.
The company is currently running a Phase I study in prostate cancer and plans to advance additional therapies into Phase I trials and IND-enabling studies next year.
The mission to move forward with addressing complications for diabetic patients, specifically diabetic nephropathy that leads to kidney disease, continues Tuesday with an increase in Series A funding (a $9 million addition that brings the total to $25 million) for the clinical-stage pharmaceutical company Vascular Pharmaceuticals, Inc. (VPI). According to a press release, existing investors […]
A biotechnology company formed by two MPM Capital managing directors to develop monoclonal antibody drugs to fight cancer has been acquired by Novartis, according to a company statement. The move follows Novartis’ deal with University of Pennsylvania to collaborate on chimeric antigen receptor technology and reflects a relatively dramatic shift in the past year toward […]
Hoping to push its groundbreaking obesity-fighting device across the proverbial finish line, EnteroMedics Inc. (NASDAQ:ETRM) is selling 12 million new shares to the public